Journal of Antimicrobial Chemotherapy (1999) 43, 31-36
© 1999 The British Society for Antimicrobial Chemotherapy
In-vitro activity of 29 antimicrobial agents against penicillin-resistant and -intermediate isolates of Streptococcus pneumoniae
a St John Hospital and Medical Center, Detroit, MI, USA b Wayne State University School of Medicine, Detroit, MI, USA c Henry Ford Hospital, Detroit, MI, USA
Antibiotic resistance among isolates of Streptococcus pneumoniae is increasing worldwide. Optimal therapy, though unknown, should be guided by in-vitro susceptibility testing. Currently, vancomycin is the only approved antibiotic that is universally active against multiresistant S. pneumoniae. In-vitro activities were determined for 29 antimicrobial agents against 22 penicillin-intermediate S. pneumoniae (PISP) and 16 penicillin-resistant S. pneumoniae (PRSP) isolates. MICs were determined in cation-adjusted Mueller–Hinton broth with 3% lysed horse blood in microtitre trays. Antimicrobial classes tested included cephalosporins, penicillin, aminopenicillins, macrolides, quinolones, carbapenems and other antimicrobial agents. Among the classes of antimicrobial agents tested, wide differences in susceptibility were demonstrated for both PISP and PRSP. Of the cephalosporins, ceftriaxone and cefotaxime demonstrated the best in-vitro activity for both PISP and PRSP. Of the quinolones, clinafloxacin and trovafloxacin showed the greatest in-vitro activity. Rifampicin and teicoplanin demonstrated excellent in-vitro activity. Promising in-vitro results of newer agents, such as quinupristin/dalfopristin, ramoplanin, teicoplanin and linezolid may justify further evaluation of these agents in clinical trials.
* Correspondence address: 22101 Moross Road, St John Hospital and Medical Center, International Medicine Administration, PB2, Detroit, MO 48236, USA. Tel:+313-343-3362; Fax:+1-313-343-7784; E-mail: omanzor{at}mindspring.com
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Brunner, H. Stass, J.-G. Moller, C. Schrolnberger, B. Erovic, U. Hollenstein, M. Zeitlinger, H. G. Eichler, and M. Muller Target Site Concentrations of Ciprofloxacin after Single Intravenous and Oral Doses Antimicrob. Agents Chemother., December 1, 2002; 46(12): 3724 - 3730. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Gentry-Nielsen, K. M. Olsen, and L. C. Preheim Pharmacodynamic Activity and Efficacy of Linezolid in a Rat Model of Pneumococcal Pneumonia Antimicrob. Agents Chemother., May 1, 2002; 46(5): 1345 - 1351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Masterton Ciprofloxacin resistance--early-warning' signs from the MYSTIC surveillance programme? J. Antimicrob. Chemother., January 1, 2002; 49(1): 218 - 220. [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Musher, J. G. Bartlett, and G. V. Doern A Fresh Look at the Definition of Susceptibility of Streptococcus pneumoniae to {beta}-Lactam Antibiotics Arch Intern Med, November 26, 2001; 161(21): 2538 - 2544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Entenza, Y. A. Que, J. Vouillamoz, M. P. Glauser, and P. Moreillon Efficacies of Moxifloxacin, Ciprofloxacin, and Vancomycin against Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus Expressing Various Degrees of Ciprofloxacin Resistance Antimicrob. Agents Chemother., November 1, 2001; 45(11): 3076 - 3083. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. McDonald, F.-J. Chen, H.-J. Lo, H.-C. Yin, P.-L. Lu, C.-H. Huang, P. Chen, T.-L. Lauderdale, and M. Ho Emergence of Reduced Susceptibility and Resistance to Fluoroquinolones in Escherichia coli in Taiwan and Contributions of Distinct Selective Pressures Antimicrob. Agents Chemother., November 1, 2001; 45(11): 3084 - 3091. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Lindler, W. Fan, and N. Jahan Detection of Ciprofloxacin-Resistant Yersinia pestis by Fluorogenic PCR Using the LightCycler J. Clin. Microbiol., October 1, 2001; 39(10): 3649 - 3655. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. N. Gilbert, S. J. Kohlhepp, K. A. Slama, G. Grunkemeier, G. Lewis, R. J. Dworkin, S. E. Slaughter, and J. E. Leggett Phenotypic Resistance of Staphylococcus aureus, Selected Enterobacteriaceae, and Pseudomonas aeruginosa after Single and Multiple In Vitro Exposures to Ciprofloxacin, Levofloxacin, and Trovafloxacin Antimicrob. Agents Chemother., March 1, 2001; 45(3): 883 - 892. [Abstract] [Full Text]
|
|
|
|
|
|
M. Boos, S. Mayer, A. Fischer, K. Köhrer, S. Scheuring, P. Heisig, J. Verhoef, A. C. Fluit, and F.-J. Schmitz In Vitro Development of Resistance to Six Quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus Antimicrob. Agents Chemother., March 1, 2001; 45(3): 938 - 942. [Abstract] [Full Text]
|
|
|
|
|
|
J. M. Sierra, J. Ruiz, M. M. Navia, M. Vargas, J. Gascon, and J. Vila In Vitro Activity of Rifaximin against Enteropathogens Producing Traveler's Diarrhea Antimicrob. Agents Chemother., February 1, 2001; 45(2): 643 - 644. [Full Text] [PDF]
|
|
|
|
|
|
K. Poole Efflux-Mediated Resistance to Fluoroquinolones in Gram-Positive Bacteria and the Mycobacteria Antimicrob. Agents Chemother., October 1, 2000; 44(10): 2595 - 2599. [Full Text]
|
|
|
|
|
|
D. F. Sahm, D. E. Peterson, I. A. Critchley, and C. Thornsberry Analysis of Ciprofloxacin Activity against Streptococcus pneumoniae after 10 Years of Use in the United States Antimicrob. Agents Chemother., September 1, 2000; 44(9): 2521 - 2524. [Abstract] [Full Text]
|
|
|
|
|
|
T. Lu, X. Zhao, and K. Drlica Gatifloxacin Activity against Quinolone-Resistant Gyrase: Allele-Specific Enhancement of Bacteriostatic and Bactericidal Activities by the C-8-Methoxy Group Antimicrob. Agents Chemother., December 1, 1999; 43(12): 2969 - 2974. [Abstract] [Full Text]
|
|